Research location

Rionero in Vulture

PZ, Italy

Published trials8

Site observations8

Linked trials published8

Page1 / 1

Research activity in Rionero in Vulture

PZ, Italy

CureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 8 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Rionero in Vulture

8 linked trials · page 1 of 1

Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate CancerNCT07093801 · 2025-07-30 · 1 site observation

stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective DatabaseNCT07397585 · 2025-02-25 · 1 site observation

Best EGFR-TKI Sequence in NSCLC Harboring EGFR MutationsNCT04811001 · 2020-06-12 · 1 site observation

Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)NCT03896074 · 2020-03-02 · 1 site observation

ACTIVE_NOT_RECRUITING

Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate CancerNCT03230734 · 2017-09-01 · 1 site observation

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung CancerNCT02566993 · 2016-08-30 · 1 site observation

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody AvelumabNCT02926196 · 2016-06-17 · 1 site observation

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.NCT02437318 · 2015-07-23 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.